# Forensic Dossier: Study Forensics: Amyloid-targeting antibody improves biomarkers without cognitive benefit

**Run ID:** `full27_study-forensics-029_Claude_Haiku_29564b`  
**Task:** study-forensics-029 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T18:01:43.404688+00:00  
**Task Family:** solid  
**Trap Type:** borderline_solid_with_caveats  
**Ambiguity:** medium  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **39.9/100** (margin: 0.0)
**Failure modes:** decorative_uncertainty, missed_key_insight, named_not_explained, overclaiming, unsupported_conclusion, wrong_answer
**Forensic flags:** 4
**Consistency findings:** 9
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 0.0/30 | 0.0/8 | 4.1/8 | 4.8/6 | 3.6/6 | 5.0/6 | 5.6/8 | 6.8/8 | 1.5/10 | 8.5/10 | **39.9/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `mechanism_vs_evidence` [x] (gold: `solid`)
**Finding Recall:** 50%
**Matched Findings:** cautious_scope_control
**Missed Findings:** evidence_matches_claim
**Extra Findings:** conclusion_exceeds_results, decorative_uncertainty, mechanism_not_demonstrated, correlation_as_causation
**False Positives:** overclaim

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "mechanism_vs_evidence"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "mechanism_vs_evidence"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "mechanism_vs_evidence"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"
- **[MINOR]** `study_forensics_overflagging`: Agent raised extra findings in solid case: conclusion_exceeds_results, decorative_uncertainty, mechanism_not_demonstrated, correlation_as_causation


## Evidence Map

### Claude Haiku

**Correctness:** 0.0/30
  - (+) `final_answer`: "mechanism_vs_evidence"
    _Agent's answer for correctness check_
  - Note: No match (got: mechanism_vs_evidence)

**Support Strength:** 0.0/8
  - (-) `final_answer`: "mechanism_vs_evidence"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[4]`: "MECHANISM VS. OVERCLAIM: The text does NOT use promotional language ('breakthrough,' 'transforms outcomes,' 'confirms ef"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[2]`: "Biomarkers (amyloid deposits, neurodegeneration markers) are surrogate endpoints, not clinical outcomes"
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.6/6
  - (+) `uncertainties[3]`: "Whether the open-label extension is being presented as a salvage attempt or as genuine next-step science (text is neutra"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.88"
    _Stated confidence level_
  - (-) `uncertainties[2]`: "Whether the inherited Alzheimer's population is representative of sporadic disease, limiting generalizability."
    _Listed but never addressed in reasoning_
  - Note: 4 uncertainties (4 substantive)
  - Note: 1 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 5.0/6
  - (+) `alternative_hypotheses[2]`: "CORRELATION_VS_CAUSATION: Not applicable here; the study is randomized, so causation is not the issue. The issue is that"
    _Most substantive alternative hypothesis_
  - Note: 3 alternative hypotheses considered
  - Note: 1/3 include rejection reasoning

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[0]`: "Did I overstate the problem? No. The text itself acknowledges the failure. The issue is that biomarker improvement is be"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.69, 601 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'solid'
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'solid', detected 'mechanism_vs_evidence'
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: correctness_
- **Overclaiming** `[HEURISTIC]`: False positive: agent flagged 'overclaim' in a solid case
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: correctness_

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: support_strength_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['effect'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: evidence_matches_claim
  - `(task expectation)`: "Expected: evidence_matches_claim"
  - _Impacts: insight_depth_

**STYLISTIC:**
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'Whether the inherited Alzheimer's population is representati...' is listed but not addressed
  - `uncertainties[2]`: "Whether the inherited Alzheimer's population is representative of sporadic disease, limiting general"
  - _Impacts: uncertainty_handling_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/11 content words)
  - `key_claims[0]`: "The drug cleared amyloid plaques and improved neurodegeneration markers — TRUE, but these are biomar"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/10 content words)
  - `key_claims[1]`: "The trial failed to show slowing of cognitive decline — TRUE, and this is the critical negative find"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/8 content words)
  - `key_claims[2]`: "Cognitive benefits remain unproven — TRUE, and this is the correct epistemic stance."
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (1/12 content words)
  - `key_claims[3]`: "The text does NOT claim the drug works; it reports a mechanism without clinical validation — this is"
- **[FAIL]** `[MEDIUM CONFIDENCE]` `assumption_reasoning`: Assumption 4 may be contradicted by step 6
  - `assumptions[3]`: "The open-label extension is uncontrolled and cannot establish efficacy"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 3 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[2]`: "Whether the inherited Alzheimer's population is representative of sporadic disease, limiting general"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "SOLID: If the text had reported that cognitive decline WAS slowed, and biomarkers improved, this wou"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 2 is stated without rejection reasoning
  - `alternative_hypotheses[1]`: "OVERCLAIM: If the text had used language like 'the drug successfully treats Alzheimer's' or 'reduces"
- **[WARN]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Phenomenon is named but causal mechanism is not explained
  - `final_answer`: "mechanism_vs_evidence"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 13943ms

**Final Answer:** mechanism_vs_evidence

**Confidence:** 0.88

**Assumptions:**
- The trial was adequately powered for cognitive endpoints (Phase 2/3 design suggests this)
- Cognitive decline was measured with validated instruments
- Biomarkers (amyloid deposits, neurodegeneration markers) are surrogate endpoints, not clinical outcomes
- The open-label extension is uncontrolled and cannot establish efficacy
- The population is inherited (early-onset) Alzheimer's disease, not sporadic disease

**Reasoning Steps:**
1. EVIDENCE TIER: The study measured biomarkers (amyloid plaques, neurodegeneration markers) in human participants. This is Tier 3 (biomarker/surrogate endpoints), not Tier 5 (clinical outcomes).
2. CONCLUSION TIER: The text implies therapeutic benefit for people with Alzheimer's disease — a human therapeutic claim (Tier 5 territory).
3. BRIDGE GAP: The trial explicitly FAILED the primary cognitive endpoint. Biomarker improvement does not establish that cognitive decline was slowed. The investigators themselves state 'cognitive benefits remain unproven.'
4. HEDGING ANALYSIS: The text does acknowledge the gap ('despite biomarker successes, the trial failed to show slowing of cognitive decline' and 'cognitive benefits remain unproven'). This is honest language, not decorative uncertainty.
5. MECHANISM VS. OVERCLAIM: The text does NOT use promotional language ('breakthrough,' 'transforms outcomes,' 'confirms effectiveness'). It is analytical and cautious. The problem is not rhetorical inflation but a genuine evidence-tier mismatch: biomarker improvement ≠ clinical benefit.
6. OPEN-LABEL EXTENSION: Proposed as next step, but uncontrolled designs cannot establish efficacy and do not bridge the gap.
7. CORE ISSUE: Amyloid clearance is a plausible mechanism, but the mechanism has not been validated by clinical outcome. The text correctly identifies this gap but still implies the drug has therapeutic potential based on biomarkers alone.

**Key Claims:**
- The drug cleared amyloid plaques and improved neurodegeneration markers — TRUE, but these are biomarkers, not clinical outcomes.
- The trial failed to show slowing of cognitive decline — TRUE, and this is the critical negative finding.
- Cognitive benefits remain unproven — TRUE, and this is the correct epistemic stance.
- The text does NOT claim the drug works; it reports a mechanism without clinical validation — this is the core forensic issue.

**Alternative Hypotheses:**
- SOLID: If the text had reported that cognitive decline WAS slowed, and biomarkers improved, this would be solid clinical evidence with a mechanistic explanation.
- OVERCLAIM: If the text had used language like 'the drug successfully treats Alzheimer's' or 'reduces cognitive decline' without acknowledging the failed endpoint, it would be overclaim.
- CORRELATION_VS_CAUSATION: Not applicable here; the study is randomized, so causation is not the issue. The issue is that the causal pathway (amyloid → cognitive benefit) was not demonstrated.

**Uncertainties:**
- Whether the cognitive endpoint was truly the primary outcome or a secondary measure (Phase 2/3 design is ambiguous).
- Whether the biomarker improvements are themselves validated surrogates for future cognitive benefit (the text does not specify).
- Whether the inherited Alzheimer's population is representative of sporadic disease, limiting generalizability.
- Whether the open-label extension is being presented as a salvage attempt or as genuine next-step science (text is neutral on this).

**Self-Verification:**
- Did I overstate the problem? No. The text itself acknowledges the failure. The issue is that biomarker improvement is being emphasized despite clinical failure, which is a classic mechanism_vs_evidence pattern.
- Did I miss that this is solid? No. A failed cognitive endpoint in a Phase 2/3 trial is a negative result. Biomarkers alone do not establish therapeutic benefit.
- Did I confuse this with overclaim? No. The text is cautious and does not make inflated claims. The problem is structural (wrong evidence tier), not rhetorical.
- Is the open-label extension a red flag? Yes, but it is presented as a next step, not as evidence. It does not change the current evidence tier.
- Did I apply the PRIORITY RULE correctly? Yes. The text is analytical, not promotional. The main problem is the evidence-tier mismatch (biomarker ≠ clinical outcome), not rhetorical inflation.

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.1/8 `#####.....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.6/6 `######....`
- Alternative Hypothesis Quality: 5.0/6 `########..`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 6.8/8 `########..`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **39.9/100**.

**Best per dimension:**
- Correctness: Claude Haiku (0.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.1/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.6/6)
- Alternative Hypothesis Quality: Claude Haiku (5.0/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (6.8/8)
- Mechanism Quality: Claude Haiku (1.5/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 13.9s | 39.9/100 | 2.9 |

Failure modes observed: decorative_uncertainty, missed_key_insight, named_not_explained, overclaiming, unsupported_conclusion, wrong_answer.
